A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole.

Gunzer, Katharina; Joly, Florence; Ferrero, Jean-Marc; Gligorov, Joseph; de Mont-Serrat, Helene; Uttenreuther-Fischer, Martina; Pelling, Katy; Wind, Sven; Bousquet, Guilhem; Misset, Jean-Louis

Gunzer, Katharina; Joly, Florence; Ferrero, Jean-Marc; Gligorov, Joseph; de Mont-Serrat, Helene; Uttenreuther-Fischer, Martina; Pelling, Katy; Wind, Sven; Bousquet, Guilhem; Misset, Jean-Louis.

Gunzer K; Oncologue-Service de Recherche Clinique, Centre François Baclesse, Avenue Général Harris, 14076 Caen Cedex 05, France.
Joly F; Oncologue-Service de Recherche Clinique, Centre François Baclesse, Avenue Général Harris, 14076 Caen Cedex 05, France ; Centre Hospitalier Universitaire Côte de Nacre, Caen, France.
Ferrero JM; Centre Antoine Lacassagne, Nice, France.
Gligorov J; APHP, HUEP-Tenon Hospital, Paris, France ; Institut Universitaire de Cancérologie, UPMC, Paris, France.
de Mont-Serrat H; Boehringer Ingelheim France S.A.S., Reims, France.
Uttenreuther-Fischer M; Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach, Germany.
Pelling K; Boehringer Ingelheim Ltd., Bracknell, UK.
Wind S; Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach, Germany.
Bousquet G; Hôpital Saint Louis, Paris, France.
Misset JL; Hôpital Saint Louis, Paris, France.